Comparative Analysis and Benchmarking:
Corporate Strategy Analysis
of Four International Pharmaceutical Companies

by
Hung-hsin Chen


DISSERTATION.COM

Parkland, FL • USA • 2003
Comparative Analysis and Benchmarking:
Corporate Strategy Analysis of
Four International Pharmaceutical
Companies

by

Hung-hsin Chen, BSc

Dissertation submitted in partial fulfilment for
the Degree of Master of Science in
Engineering Business Management

Department of Engineering
University of Warwick
September 1998
Abstract

This research of corporate strategy analysis implements comparative analysis and benchmarking to analyse and examine the corporate strategy of the pharmaceutical sectors of 4 international pharmaceutical companies.

Most existing studies of pharmaceutical industry have been limited to some specific fields such as the R&D ability, new products launch time, acquisitions, and alliances. Little has been known about the analysis of corporate strategy and comparison of pharmaceutical industry by both internal and external factors. On the other hand, the comparative strategy and benchmarking have been frequently applied in analysing the corporate strategy mostly in public service industries, in financial and accounting industry, and in insurance industry. Little has been applied to examine and analyse the corporate strategy of research-based industries such as pharmaceutical industry. This research aims to fill the gap by implementing these two techniques to analyse and examine the corporate strategies of 4 research based pharmaceutical companies.

This research adopts the hybrid approach of combining qualitative and quantitative methods in a two stages research design. Quantitative method is applied first to deal with the comparative figures, and then qualitative method is used to find out the problem. The design of this multiple research includes three phases: data collection, analysis, and reporting.

The findings of this research can be divided into 4 parts: R&D/marketing, technology alliances, strategic acquisitions and merger, and manufacturing. The drug innovative projects are recommended being developed within the company's familiar therapeutic areas in order to take its marketing advantage. Through this comparative analysis, some of this type of problems of these international pharmaceutical companies is identified. A big pharmaceutical company forming alliances with some small biotechnology companies has become a trend within pharmaceutical industry since 1980s. For pharmaceutical companies, to take advantage of R&D through biotechnology is the main purpose of alliances with small biotechnology companies. It is important to note that most pharmaceutical acquisitions belong to the type of absorption with high resource transferring and low autonomy. Due to the high profit margin and the essential importance of R&D and marketing, the operation management of manufacturing of pharmaceutical industry is relatively poor. The low asset utilisation rate pointed out this problem. Academic researches have revealed that existing theories of operation management of manufacturing, such as action research, set-up reduction, teamwork, continuous improvement, collaboration, and involvement, are applicable and beneficial to pharmaceutical industry rather than waiting for the technology breakthroughs.
Acknowledgement

While studying the corporate strategy analysis, I have gained fruitful knowledge to analyze the corporate strategy of research based companies. In addition, I have also encountered some difficulties in my life in this country that is completely new to me. Therefore, apart from people who have offered their great help in the academic work, this acknowledgement is also addressed to those who have motivated and encouraged me during this year.

I would like to express my great gratitude to my supervisors, Mr. Peter du Feu and Mr. John Hartland, who have constantly provided me with their support, encouragement, and guidance. Their positive and assuring attitude on my ability to succeed in the MSc has been most critical in building up my confidence.

In addition, I would like to express my appreciation to Dr. I. R. Pashby, Dr. A. Dowd, Mr. L. Wang, Mr. S. L. Pan, Mr. Y. F. Foo, D. Wang, Mr. B. Yang, Mr. C. Shih, Ms. P. Lee, and Ms. C. Lambert who have offered valuable advice, help, and encouragement in my MSc study.

My parents' devoted love and unfailing encouragement have been the major motivator behind every progress of mine.

There are so many people to whom I owe a great deal who have offered their generous help at different stages of my MSc study. In addition, a number of staffs and my classmates in the Warwick Manufacturing Group and staffs in the corporate information library have offered their help during the research stages of this dissertation.
III

Declaration

I, Hung-hsin Chen, declare that all information presented in this project has been compiled by me. Any quoting is stated as so, and when references are made to previous work, they appear as references at the end of the report.

No part of this dissertation has been submitted in support of an application for another degree or qualification from this university or any other institute of learning.

Hung-hsin Chen
1st September 1998
# Table of Contents

Abstract I  
Acknowledgement II  
Declaration III  
Table of Contents IV  
List of Tables VII  
List of Figures VIII

1. Introduction 1  
1.1 Research Background 2  
1.2 Organisation of the Dissertation 5

2. Literature Review 9  
2.1 Introduction 10  
2.2 Marketing Strategy 11  
2.3 R&D/Marketing 13  
2.4 Generics 15  
2.5 Government Regulation 16  
2.6 Alliances 17  
2.7 Acquisitions 18  
2.8 Manufacturing 21

3. Research Theoretical Framework 25  
3.1 Introduction 26  
3.2 Existing Theoretical and Empirical Studies of Comparative Analysis 27  
3.3 Existing Theoretical and Empirical Studies of Benchmarking 32

4. Research Methodology 36  
4.1 Introduction 37  
4.2 Research Design 38  
4.3 Data Collection 39
List of Tables

Table 5.5-1: British Industrial Performance Comparisons 50
Table 5.5-2: British Industrial Performance Comparisons 51
Table 5.5-3: British Industrial Performance Comparisons 52
Table 5.5-4: British Industrial Performance Comparisons 53
Table 5.5-5: British Industrial Performance Comparisons 54
Table 6.1-1: Comparisons on revenue, profit, and global market share 58
Table 6.2-1: Global pharmaceutical markets by geographic areas 61
Table 6.2.1.2-1: Sales by geographic region of Glaxo Wellcome 62
Table 6.3-1: Comparison of turnover by therapeutic areas 72
Table 6.3-2: Comparison of turnover by therapeutic areas 73
Table 6.3-3: Comparison of turnover by therapeutic areas 74
Table 6.3-4: Comparison of turnover by key products 75
Table 6.3-5: Comparison of turnover by key products 76
Table 6.3-6: Comparison of turnover by key products 77
Table 6.3-7: Comparison of turnover by key products 78
Table 7.2-1: Comparisons of R&D investments 88
Table 7.2-2: Comparisons of R&D investments 89
Table 7.3-1: Comparison of New Products 92
Table 8.2.2-1: SmithKline Beecham's pharmaceuticals of asthma therapy 104
Table 8.3-1: Some alliances between genomics and big pharmaceuticals 106
Table 8.3-2: Top biotechnology companies 108
List of Figures

Figure 2.2-1: The Ansoff Matrix 11

Figure 2.3-1: The 5 dimensions of R&D/marketing interface in drug innovation 13

Figure 2.3-2: Classification of innovation projects by market and technology environment 14

Figure 2.7-1: Types of acquisitions 19

Figure 3.2.2-1: Choosing companies for the purposes of inter-company comparisons 30

Figure 3.3.5-1: Benchmarking at three levels 34

Figure 5.5-1: Return on capital and pre-tax profit margin 49

Figure 6.1-1: Comparison on revenue 56

Figure 6.1-2: Comparison on profit 57

Figure 6.1-3: Comparison on global market share 57

Figure 6.2-1: Global pharmaceutical markets by geographic areas 59

Figure 6.2-2: Global pharmaceutical markets by geographic areas 59

Figure 6.2-3: Global pharmaceutical markets growth rate by geographic areas 60

Figure 6.2-4: Global pharmaceutical markets growth rate by geographic areas 60

Figure 6.3-1: Comparison of turnover by therapeutic area: cardiovascular 66

Figure 6.3-2: Comparison of turnover by therapeutic area: gastro-intestine 66

Figure 6.3-3: Comparison of turnover by therapeutic area: anti-bacteria 67

Figure 6.3-4: Comparison of turnover by therapeutic area: anti-virus 67

Figure 6.3-5: Comparison of turnover by therapeutic area: CNS 68

Figure 6.3-6: Comparison of turnover by therapeutic area: respiratory 68

Figure 6.3-7: Comparison of turnover by therapeutic area: oncology 69

Figure 6.3-8: Comparison of turnover by therapeutic area: dermatology 69

Figure 6.3-9: Comparison of turnover by therapeutic area: anaesthesia 70
Figure 6.3-10: Comparison of turnover by therapeutic area: NSAID 70
Figure 6.3-11: Comparison of turnover by therapeutic area: immunology 71
Figure 6.3-12: Comparison of turnover by therapeutic area: metabolism 71
Figure 7.2-1: Comparisons of R&D investment of 4 pharma companies 87
Figure 7.2-1: Comparisons of R&D investment as % of sales 87
Figure 7.3-1: Product development pipeline of Novartis 94
Figure 7.3-2: Product development pipeline of Glaxo Wellcome 94
Figure 7.3-3: Product development pipeline of SmithKline Beecham 95
Figure 7.3-4: Product development pipeline of Zeneca 95
Figure 8.3-1: Market share of 1997 top biotechnology companies 107
Figure 8.3-2: Market share of top 10 pharma companies 107
1. Introduction

Research Background

Organisation of the Dissertation


1.1 Research Background

British pharmaceutical industry is very successful and is only second to the US. In 1996, British pharmaceutical industry showed a trade surplus of £2,250 million for Britain, second only to North Sea Oil (ABPI, 1997).

Most existing studies of pharmaceutical industry have been limited to some specific fields such as the R&D ability, new products launch time, acquisitions, and alliances. Little has been known about the analysis of corporate strategy and comparison of pharmaceutical industry by both internal and external factors.

The comparative analysis and benchmarking are techniques in the area of strategy analysis. They are useful to help analyse the strategy of company from the aspects both of relative position and of absolute position. Numerous studies have identified the comparative analysis and benchmarking are essential tools for strategy analysis. In addition, previous research has successfully implemented comparative analysis and benchmarking to examine the strategy of different industries.

Three British pharmaceutical companies and one Swiss pharmaceutical company are selected. All of them are top 20 companies in the pharmaceutical industry worldwide. These 3 British pharmaceutical companies, Glaxo Wellcome, SmithKline Beecham, and Zeneca, own 61% of the sales amount of British pharmaceutical industry, which consists of 80 pharmaceutical companies. Novartis, the Swiss pharmaceutical company, is the largest global life science company. In
global pharmaceutical industry, these 4 companies are in similar situation and operate in the same field.

Academic researches have defined the marketing and R&D as main activities within a research based industry such as the pharmaceutical industry. Therefore, in this research, figures related to marketing and R&D collected from these 4 pharmaceutical companies are mainly selected to be compared. It is important to note that due to the significantly different characteristics between pharmaceuticals and other products, data is only selected and collected from the pharmaceutical sector of these companies in this research.

As a result of this population selection, it is not appropriate to apply findings from this research to other industry. Nevertheless, the design of the research theoretical framework is not constraint to a particular industry. With certain adjustment on the measurements of some constructs, the research framework should be applicable to other industries.

In the current research, special effort has been made to ensure the reliability of the data. Multiple data collection methods including statistic data from industry reports, operational reviews of companies, journals, news released by companies, related associations, government departments, official organisations, and empirical research findings from academic journals, dissertations, books and doctoral thesis were all applied. Every comparative figure was carefully prepared by reading in advance associated empirical theories and studying the background information relating to the company and industry. In addition, all comparative figures, analysis, and findings were sent to supervisors for comments and error correction.
1.2 Organisation of the Dissertation

The dissertation is organised into 9 chapters.

In chapter 1, a completed introduction of this dissertation is placed to clearly outline the main body of this dissertation. There are two parts in this chapter: research background and structure of this dissertation. Research background explains the reason why this research being done, mentions how this being carried out, and shows the potentially academic contributions. The second part, organisation of this dissertation, expresses a clear structure of the main body of this dissertation.

In chapter 2, an overview of previous studies in the pharmaceutical industry is provided. Empirical researches related to the activities of pharmaceutical industry are also discussed, in which some existing theories will be applied to examine the results found by comparative analysis and benchmarking. There are 6 sections in this chapter: R&D/marketing, competition from generics, impact from governmental regulation, alliances, acquisitions, and marketing strategy.

The implementation of comparative analysis and benchmarking to international pharmaceutical companies is an application of analysis issue in which the comparative analysis and benchmarking are implemented to analyse the corporate strategy of these four international pharmaceutical companies. Therefore, in chapter 3, the existing theories within this chapter are described by two main subtopics, comparative analysis and benchmarking. In the part of comparative analysis,
theories of historical analysis, inter-company comparison, and comparison with industrial norms are introduced. In the second part, benchmarking are discussed in details. These theories will be use as frameworks to analyse the corporate strategies of the 4 international pharmaceutical companies which we chose.

In chapter 4, the research methodology is provided. This research implements a multiple approach. Both quantitative and qualitative approaches are applied in this research. This research adopts the hybrid approach of combining qualitative and quantitative methods in a two stages research design. Quantitative method is applied first to deal with the comparative figures, and then qualitative method is used to try to find out the key matters. The design of this multiple research includes three phases: data collection, analysis, and reporting.

In chapter 5, the industry background is provided to help understanding the specified issues we discussed in this research. The pharmaceutical business environment is dominated by regulation and legislation designed to benefit most of society, which leads to more generics products, increasing substitution, more strict price control, and escalated R&D cost. The most distinct feature of pharmaceutical industry is its two-layers of customers: general practitioners (GPs) and patients. The GPs who are purchasing decision-makers don't consume the products themselves. The bill of medicines is directly paid by the healthcare systems of governments, neither by GPs nor by patients. Government regulations strongly enforce on the companies, concerning every aspect including marketing, pricing, advertising, distribution, and innovation. Innovation plays a major role in the success of global pharmaceutical industry. Pharmaceutical companies continue to increase their
investment on R&D. R&D become the major principle of all activities in the pharmaceutical companies such as the marketing and the manufacturing.

In chapter 6, figures of pharmaceutical markets in terms of geographic and therapeutic areas are compared. Turnover is a major indicator of how strong a company is in its field. Similar to consumer products, the success of pharmaceuticals can be shown by their sales amount, both relatively and independently. Pharmaceutical markets can be shown by different bases of comparative figures such as geographic markets, therapeutic markets, and markets of major products; segmented markets contribute to the precision of analysis. In this chapter, each market will be compared and analysed by historical analysis, inter-company comparisons, and benchmarking.

In chapter 7, figures of pharmaceutical R&D in terms of R&D investment, new products, and product development pipeline are compared. Empirical research shows that the pharmaceutical industry's success is associated directly with its substantial and sustained commitment to research and development. By comparing these figures, it is helpful for us to investigate the development of these pharmaceutical companies (Gilmartin, 1997)

In chapter 8, through the comparative figures, some meaningful and interesting points are signified. In addition to applying the existing theories of corporate strategy of pharmaceutical industry, some special characteristics and problems within these four pharmaceutical companies can be clearly identified. Further more, some existing theories of pharmaceutical corporate strategy can be further proved and developed.
In chapter 9, a short summary of important research findings is provided to clearly present the important points developed through the whole research.
2. Literature Review

Introduction

Marketing Strategy

R&D/Marketing

Generics

Government Regulation

Alliances

Acquisitions
### 2.1 Introduction

Pharmaceutical industry is a research-based industry. The existing theories of pharmaceutical corporate strategy have been extensively developed. In this chapter, an overview of previous studies in the pharmaceutical industry is provided. Empirical researches of related activities of pharmaceutical industry are also discussed, in which some existing theories will be applied to examine the results developed by comparative analysis and benchmarking.
2.2 **Marketing Strategy**

Due to the decreasing profit margin, more and more marketing strategies are implemented by pharmaceutical companies to sustain and to neutralise the impact of pharmaceutical price regulation such as gaining better control of distribution, getting closer to customers, moving to disease management, and exploring markets in the developing countries (Smith, 1998).

![Figure 2.2-1: The Ansoff Matrix](image)

The portfolio strategy is frequently used to contribute both to innovation management and to marketing strategies in the pharmaceutical industry. According to Ansoff (1987), the portfolio strategy specifies the position of a company which can be conceived as an assembly of strategic business areas; each of these areas offers different competitive approaches (Figure 2.2-1).
The 4 strategic business areas are:

- **Market penetration** denotes a growth direction of the increasing market share for the present product-market.

- In **market development**, new missions are sought for the company's products.

- **Product development** creates new products to replace current ones.

- In **Diversification**, both products and missions are new to the company.
2.3 R&D/Marketing

The R&D and marketing are two major activities within the pharmaceutical industry. Therefore, it is important to find out the relationship between R&D and marketing, which contributes both to innovation management and to marketing strategy of pharmaceutical industry. Important theories of the interface of R&D and marketing have been developed; the role of the R&D/marketing interface in pharmaceutical innovation covers the five dimensions (Figure 2.3-1):

![Figure 2.3-1: The 5 dimensions of R&D/marketing interface in drug innovation](image)

<table>
<thead>
<tr>
<th>Corporate</th>
<th>Strategic</th>
<th>Technical</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Corporate strategic dimension</td>
<td>2. Corporate technical dimension</td>
</tr>
<tr>
<td></td>
<td>5. Operational dimension</td>
<td></td>
</tr>
</tbody>
</table>


According to Wang (1993), the effectiveness of the 5 dimensions is influenced both by the market and by the technology environment. Six classifications of innovation projects are defined as below (Figure 2.3-2). Wang (1993) concludes that the R&D/marketing interface tends to be most effective in a "related technology and